Nurix Price To Free Cash Flows Ratio from 2010 to 2024

NRIX Stock  USD 22.11  0.88  4.15%   
Nurix Therapeutics Price To Free Cash Flows Ratio yearly trend continues to be fairly stable with very little volatility. Price To Free Cash Flows Ratio will likely drop to -3.56 in 2024. During the period from 2010 to 2024, Nurix Therapeutics Price To Free Cash Flows Ratio regression line of annual values had significance of  0.79 and arithmetic mean of (63.27). View All Fundamentals
 
Price To Free Cash Flows Ratio  
First Reported
2010-12-31
Previous Quarter
(3.39)
Current Value
(3.56)
Quarterly Volatility
180.528534
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Nurix Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nurix Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 13.4 M or Interest Income of 13.4 M, as well as many indicators such as Price To Sales Ratio of 4.8, Dividend Yield of 0.0 or PTB Ratio of 1.59. Nurix financial statements analysis is a perfect complement when working with Nurix Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Nurix Therapeutics Correlation against competitors.
For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

Latest Nurix Therapeutics' Price To Free Cash Flows Ratio Growth Pattern

Below is the plot of the Price To Free Cash Flows Ratio of Nurix Therapeutics over the last few years. It is Nurix Therapeutics' Price To Free Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nurix Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price To Free Cash Flows Ratio10 Years Trend
Very volatile
   Price To Free Cash Flows Ratio   
       Timeline  

Nurix Price To Free Cash Flows Ratio Regression Statistics

Arithmetic Mean(63.27)
Coefficient Of Variation(285.33)
Mean Deviation96.12
Median(9.20)
Standard Deviation180.53
Sample Variance32,591
Range700
R-Value(0.08)
Mean Square Error34,898
R-Squared0.01
Significance0.79
Slope(3.05)
Total Sum of Squares456,268

Nurix Price To Free Cash Flows Ratio History

2024 -3.56
2023 -3.39
2022 -3.77
2021 -3.5
2020 -13.73
2019 -144.18
2018 -703.28

About Nurix Therapeutics Financial Statements

Nurix Therapeutics investors use historical fundamental indicators, such as Nurix Therapeutics' Price To Free Cash Flows Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Nurix Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Free Cash Flows Ratio(3.39)(3.56)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.